New chemo listing in indolent Non-Hodgkin’s Lymphoma

A cancer medicine that doubles progression free survival in people with indolent Non-Hodgkin’s Lymphoma and is less toxic than previous chemotherapy regimens will be added to the Pharmaceutical Benefits Scheme on 1 May. Australian haematologists have welcomed the PBS listing of Ribomustin (bendamustine hydrochloride) for the first-line treatment of indolent Non-Hodgkin’s Lymphoma and Mantle Cell

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Forgot Password?Why do I need to login & stay in?

Previous Vaccine refusal stays largely unchanged
Next New therapies for hep C listed